Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New US Cholesterol Guidelines Hit PCSK9s Hard On Pricing, Value

Executive Summary

Already outdated? The latest ACC/AHA guidelines say at mid-2018 list prices, PCSK9 injectables are of low value, but the costs have plummeted since then.

Advertisement

Related Content

Sanofi's Vaccines Performance Helps Offset Diabetes Decline
Amgen Drops Repatha List Price 60% To Cut Medicare Co-Pays And Boost Use
PCSK9 Inhibitor Labeling Parity Is Within Reach As Praluent And Repatha Strive To Make Commercial Case
Let's Make A Deal: Sanofi/Regeneron Extend A Hand On Praluent, Express Scripts Takes It
PCSK9 Turning Point? Sanofi/Regeneron Dangle Lower Price Carrot For Praluent
PCSK9 Sales Still Slow, But May Get Boost From Label, Guideline Changes
Is Amgen's FOURIER Enough For Physicians, Payers To Expand Repatha Use?
Merck Fails To Win Zetia/Vytorin CV Risk Reduction Claim
Time, And Price, Are Right To Prescribe Statins To the Masses

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124186

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel